This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
RAP1B / Ras-related protein Rap-1b · Western blot design guide
Design a Western Blot for RAP1B
Real validated RAP1B Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-RAP1B WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
RAP1B Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~20.8 kDa | |
| Gel | 12–15% (standard starting point) | |
| Negative control | Suggested KO / knockdown lysate |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Phosphorylated + Methylated | |
| Caveat | Modification-state controls | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 4 isoform(s) |
Section 1
Real Curated RAP1B Western Blot Protocols
The A02596-1 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | Target-positive lysate and matched negative control (standard starting point) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Short semi-dry transfer; verify retention (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | A02596-1; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected RAP1B Western Blot Band Size?
RAP1B is predicted at 20.8 kDa; propeptide cleavage and isoforms could affect appearance, but their effects on migration are unproven.
| Band near 20.8 kDa | Consistent with the predicted RAP1B size; confirm identity with a RAP1B control. |
| Band slightly below 20.8 kDa | Could reflect removal of the 182–184 propeptide, though a visible shift is unproven. |
| Several bands near the predicted size | Isoforms 1, 2, 3, and 4 are annotated, but distinct migration is unproven. |
| Band in membrane and cytosolic fractions | Consistent with RAP1B localization in both compartments. |
💡Expected RAP1B appearanceRAP1B has a predicted mass of 20.8 kDa, but no empirical band size is supplied; use a RAP1B identity control before assigning a band, since cleavage and isoform effects on migration are unproven.
| UniProt predicted mass | Sets a 20.8 kDa reference for RAP1B. |
| Propeptide at residues 182–184 | Cleavage would remove three residues, with no established visible shift. |
| Splice isoforms 1 and 2 | Their apparent sizes relative to each other are not supplied. |
| Splice isoforms 3 and 4 | Their apparent sizes relative to each other are not supplied. |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | RAP1B may be partitioned between membrane and cytosolic compartments. | Check both fractions and verify sample loading. |
| Band higher than expected | Its identity or apparent migration is uncertain; no higher-mass RAP1B band is established. | Confirm with an independent RAP1B antibody or depletion control. |
| Band lower than expected | Propeptide removal is annotated, but cannot establish a resolvable shift. | Confirm band identity and compare with the predicted 20.8 kDa reference. |
| Multiple bands | Four isoforms are annotated, but distinct bands are unproven. | Check which bands respond to RAP1B depletion. |
| Weak or no signal | RAP1B distribution across membrane and cytosol may affect recovery. | Check extraction of both fractions and verify antibody performance with a positive control. |
| Fragments below expected size | Small fragments are not explained by the annotated three-residue propeptide. | Check sample integrity and test fragment identity with RAP1B depletion. |
Experiment evidence
Western blot images showing RAP1B band
A02596-1 · RAP1B
A02596 · RAP1B
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for RAP1B Western blot
🧪For positive controls for RAP1B in Western blot, you can use no HPA-supported tissue or cell line because no expression data were supplied.
Positive control: No high/medium HPA tissue identified
Negative control: Suggested KO / knockdown lysate
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: Without HPA expression data, tissue controls cannot be validated; a knockdown or KO line can provide a negative control.
HPA tissue expression evidence for RAP1B
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No lower-expression tissue rows available in the supplied evidence. | ||||
Section 3
Advanced RAP1B Western Blot Tips
Deeper troubleshooting and optimisation questions for RAP1B, answered from its protein features.
How should RAP1B band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
How might RAP1B isoforms affect band interpretation?
Isoforms · Four isoforms are listed. Relative to the canonical sequence, isoform 2 lacks residues 62..108, isoform 3 lacks 43..61, and isoform 4 lacks 20..61. Check whether the antibody epitope falls within a deleted region before assigning bands to isoforms.
Which RAP1B modifications matter when interpreting bands?
PTM · Using the supplied UniProt coordinates, Ser39 is ADP-ribosylated by botulinum toxin, Ser179 is phosphorylated by PKA, and Cys181 is a cysteine methyl ester. These sites identify possible modified forms; they do not establish that separate bands will be visible. Isoform 4 lacks canonical residue 39.
Does this guide establish induction of RAP1B?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for RAP1B?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A02596-1 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
What should be considered when quantifying RAP1B across samples?
Quantitation · Decide whether the measurement represents total RAP1B or a particular fraction or isoform. The listed membrane–cytosol distribution can change, and isoforms 2–4 contain distinct deletions. An antibody epitope within a deleted region would prevent that isoform from contributing to the measured signal.
Should RAP1B run at its predicted 20.8 kDa?
Interpretation · 20.8 kDa is the predicted mass; no observed band position is supplied. UniProt lists a propeptide at residues 182..184 and several modifications, but these features alone do not establish a visible shift or explain any difference from 20.8 kDa.
Consider the recorded conditions when interpreting treated samples: UniProt assigns Ser39 ADP-ribosylation to botulinum toxin and Ser179 phosphorylation to PKA. A band change cannot be attributed to either modification from this feature list alone. Positions refer to the supplied UniProt sequence and may differ from antibody or paper numbering.
RAP1B is listed at the cell membrane, in the cytosol, and at cell junctions, and may shuttle between membrane and cytosol. For fraction comparisons, measure the fractions consistently; a change in one fraction may reflect redistribution. Junction localization requires KRIT1 and CDH5 according to the supplied annotation.
Compare bands with the predicted 20.8 kDa mass and the listed isoform deletions, then check the antibody epitope against those regions. Consider the recorded Ser39, Ser179, and Cys181 modifications and propeptide 182..184, while recognizing that their presence does not establish a visible shift. No empirical band size is supplied.
Consider the recorded conditions when interpreting treated samples: UniProt assigns Ser39 ADP-ribosylation to botulinum toxin and Ser179 phosphorylation to PKA. A band change cannot be attributed to either modification from this feature list alone. Positions refer to the supplied UniProt sequence and may differ from antibody or paper numbering.
RAP1B is listed at the cell membrane, in the cytosol, and at cell junctions, and may shuttle between membrane and cytosol. For fraction comparisons, measure the fractions consistently; a change in one fraction may reflect redistribution. Junction localization requires KRIT1 and CDH5 according to the supplied annotation.
Compare bands with the predicted 20.8 kDa mass and the listed isoform deletions, then check the antibody epitope against those regions. Consider the recorded Ser39, Ser179, and Cys181 modifications and propeptide 182..184, while recognizing that their presence does not establish a visible shift. No empirical band size is supplied.
Boster reagents
RAP1B Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-Ras-related protein Rap-1b RAP1B Antibody
Cat # A02596-1
Real WB data
Anti-Ras-related protein Rap-1b RAP1B Antibody
Cat # A02596
Two the supplier anti-RAP1B antibodies have WB images: A02596-1 with A431 lysate at 1:1000 after overnight incubation at 4°C, and A02596 with extracts from various cell lines at 1:3000. These examples do not establish performance across every listed species.
Which to pick: Choose A02596-1 if the documented A431 blot matches your sample; choose A02596 for its documented blot of various cell-line extracts. Both list human and mouse reactivity; only A02596-1 lists rat. The captions do not establish rat WB performance.
Source: BosterBio RAP1B gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry P61224.
- Human Protein Atlas. RAP1B tissue expression.
- PMC7366005 — target-verified WB comparison
- PMC12244390 — target-verified WB comparison
- PMC5153279 — target-verified WB comparison